- Report
- February 2025
- 204 Pages
Global
From €4217EUR$4,799USD£3,637GBP
- Report
- May 2025
- 187 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- May 2025
- 194 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- April 2025
- 200 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- July 2025
- 192 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- February 2025
- 182 Pages
Global
From €3361EUR$3,825USD£2,899GBP
€3954EUR$4,500USD£3,411GBP
- Newsletter
- July 2025
Global
€2632EUR$2,995USD£2,270GBP
- Report
- June 2025
- 105 Pages
Global
From €3031EUR$3,450USD£2,615GBP
- Report
- March 2023
- 300 Pages
Global
From €4217EUR$4,799USD£3,637GBP
- Report
- August 2019
- 519 Pages
Global
From €3953EUR$4,499USD£3,410GBP
- Book
- April 2021
- 464 Pages

The Dendritic Cell market is a subset of the biotechnology industry that focuses on the development of treatments and therapies based on dendritic cells. Dendritic cells are a type of immune cell that play a key role in the body's immune response. They are responsible for recognizing and responding to foreign substances, such as viruses and bacteria, and initiating an immune response. As such, they are a promising target for the development of treatments for a variety of diseases.
The Dendritic Cell market is composed of a variety of companies, ranging from large pharmaceutical companies to small biotechnology startups. These companies are focused on developing treatments and therapies based on dendritic cells, as well as researching new ways to use them in the treatment of diseases.
Some of the companies in the Dendritic Cell market include Novartis, Merck, Pfizer, Celgene, and Gilead Sciences. Additionally, there are a number of smaller biotechnology companies, such as Immunovant, Immunocore, and Adaptimmune, that are focused on developing treatments and therapies based on dendritic cells. Show Less Read more